Key Points
- Joshua Schafer sold 10,500 shares of Zevra (NASDAQ:ZVRA) on Feb. 3 at an average price of $9.19 for $96,495, cutting his stake by 14.43% to 62,278 shares; he also sold 3,375 shares on Jan. 30 at $8.83.
- Zevra has a market cap of about $503.3M and a PE of 19.02, reported quarterly EPS of ($0.01) (beating estimates) with revenue slightly below expectations, and carries a consensus analyst rating of Moderate Buy with an average target of $22.80.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of Zevra Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares in the company, valued at $271,636.20. This represents a 9.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Zevra Therapeutics Stock Performance
NASDAQ:ZVRA opened at $9.02 on Thursday. The company has a fifty day moving average of $8.68 and a two-hundred day moving average of $9.40. Zevra Therapeutics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The stock has a market capitalization of $507.77 million, a PE ratio of 18.91 and a beta of 0.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. The business had revenue of $26.06 million during the quarter, compared to analysts' expectations of $26.64 million. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. As a group, research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Bailard Inc. acquired a new stake in Zevra Therapeutics during the 4th quarter valued at $116,000. UBS Group AG lifted its position in shares of Zevra Therapeutics by 30.9% in the fourth quarter. UBS Group AG now owns 285,488 shares of the company's stock valued at $2,558,000 after acquiring an additional 67,392 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in shares of Zevra Therapeutics by 18.0% during the fourth quarter. Sanctuary Advisors LLC now owns 34,461 shares of the company's stock valued at $309,000 after acquiring an additional 5,247 shares during the last quarter. Retirement Planning Co of New England Inc. increased its position in Zevra Therapeutics by 10.4% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company's stock worth $5,940,000 after purchasing an additional 62,206 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its stake in Zevra Therapeutics by 78.6% in the 4th quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company's stock valued at $3,665,000 after purchasing an additional 180,000 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on ZVRA. Weiss Ratings reiterated a "sell (d+)" rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, November 8th. HC Wainwright set a $26.00 price target on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Thursday, November 6th. Finally, Cantor Fitzgerald cut their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an "overweight" rating for the company in a report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.80.
Read Our Latest Analysis on ZVRA
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
